ELOXATIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eloxatin, and what generic alternatives are available?
Eloxatin is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eloxatin
A generic version of ELOXATIN was approved as oxaliplatin by HOSPIRA WORLDWIDE on August 7th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ELOXATIN?
- What are the global sales for ELOXATIN?
- What is Average Wholesale Price for ELOXATIN?
Summary for ELOXATIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 333 |
| DailyMed Link: | ELOXATIN at DailyMed |
Recent Clinical Trials for ELOXATIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Puma Biotechnology, Inc. | Phase 2 |
| First Affiliated Hospital of Guangxi Medical University | Phase 2 |
| Mayo Clinic | Phase 1 |
Paragraph IV (Patent) Challenges for ELOXATIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ELOXATIN | Injection | oxaliplatin | 5 mg/mL, 40 mL vials | 021759 | 1 | 2007-07-16 |
| ELOXATIN | Injection | oxaliplatin | 5 mg/mL, 10 mL and 20 mL vials | 021759 | 11 | 2007-02-09 |
US Patents and Regulatory Information for ELOXATIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021492-001 | Aug 9, 2002 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021759-002 | Jan 31, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021759-001 | Jan 31, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021492-002 | Aug 9, 2002 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021759-003 | Nov 17, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ELOXATIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021759-001 | Jan 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021492-001 | Aug 9, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021759-001 | Jan 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021759-003 | Nov 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 021492-002 | Aug 9, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ELOXATIN
See the table below for patents covering ELOXATIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 114852 | Pharmaceutically stable preparation of oxaliplatinum | ⤷ Sign Up |
| Russian Federation | 2148400 | PHARMACEUTICALLY STABLE PREPARATION OF OXALYPLATINUM | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 9604904 | ⤷ Sign Up | |
| Spain | 2125320 | ⤷ Sign Up | |
| Germany | 69519300 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
